Mumbai, July 16 -- The approval is for an additional indication of Benralizumab 30 mg/ml solution for injection in a pre-filled syringe (brand name: Fasenra). The drug is now indicated for the treatment of patients aged 12 years and above with hypereosinophilic syndrome (HES) without an identifiable non-haematologic secondary cause.

The receipt of this permission paves the way for the marketing of Benralizumab 30 mg/ml solution for injection in a pre-filled syringe (brand name: Fasenra) in India for the specified additional indication, subject to receipt of related statutory approvals, if any.

AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in four ...